Patients in future trials of CF101 will be able to take it for 6 -12 months or longer.
Can-Fite BioPharma Ltd. (TASE:CFBI) has successfully completed preclinical long-term toxicology studies for its CF101 drug for rheumatoid arthritis as required by the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA). The success of these studies will enable patients participating in future clinical trials to take the drug for 6 -12 months or longer, as is generally required in phase III clinical trials.
In January, Can-Fite announced the enrolment of about 250 patients in a phase IIb RA clinical trial in the US, Europe and Israel, in which CF101 was given for 12 weeks. The results of this trial are due to be released this summer.
In addition to the rheumatoid arthritis trial with CF101, Can-Fite has initiated concurrent clinical trials for two other indications of the drug: dry eye syndrome (Keratitis sicca) and psoriasis. Can-Fite has already signed its first commercial contract for CF101 with Seikagaku Corporation (TSE:4548) of Japan, under which Can-Fite has already received $5 million. The company is also developing CF102 for the treatment of liver cancer and hepatitis B.
Published by Globes [online], Israel business news - www.globes.co.il - on June 3, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007